/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
解毒与急救
/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
非人类毒性摘录
实验室动物：急性暴露/对兔眼无刺激性。
/LABORATORY ANIMALS: Acute Exposure/ Not irritating for rabbit eye.
/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Exposure levels: 0, 0.1, 0.3, and 1.0% in diet; Actual doses received: Males: 0, 81, 246, 871 mg/kg; Females: 0, 86, 259, 894 mg/kg. Repeated oral-dose toxicity /in/ Sprague-Dawley (CD(SD)BR) /rats (males and females 5/sex) for/ 4-weeks...Rats, were approximately 6-7 weeks in age and weighed 177 g (males) and 143 g (females) at study initiation. Animals were weighed and had detailed clinical observations recorded on Days 0, 4, 7, 14, 18, 22, and 29. Feed intake was assessed twice/week. At termination hematology (Hb conc., Hct, RBC count and morphology, WBC count and diff., and plt. Count) and clinical chemistries (AST, ALT, SDH, ALK, Creat., BUN, and gluc.) were conducted. At termination, animals underwent a gross examination with the following organs weighed: liver, spleen, kidneys, adrenals, testes, and thymus. Organs examined by histology included: trachea, lungs, heart, esophagus, stomach, small & large intestine, pancreas, liver, salivary glands, kidney, urinary bladder, pituitary, adrenals, thyroids, parathyroids, thymus, spleen, mesenteric lymph nodes, bone marrow, brain, testes, epididymis, accessory sex organs in males, fallopian tubes, uterus, vagina and ovaries. NOAEL (NOEL): 1.0%; [871 mg/kg (males) and 894 mg/kg (females)]. There were no mortalities or clinical signs related to exposure. There were no differences in body weights, feed consumption, hematology, clinical chemistries, and organ weights compared to controls. There were no gross or histological changes observed. CHDA induced essentially no toxicity following 4 weeks of exposure at a high exposure rate (1% of diet).
[EN] BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS [FR] COMPOSÉS BICYCLIQUES PONTÉS POUR LE TRAITEMENT DES INFECTIONS BACTÉRIENNES
[EN] CONTINUOUS DEHYDROGENATION OF 1,4-CARBOXYLATE SUBSTITUTED CYCLOHEXENES [FR] DÉSHYDROGÉNATION EN CONTINU DE CYCLOHEXÈNES SUBSTITUÉS PAR 1,4-CARBOXYLATE
[EN] PROCESS FOR THE PREPARATION OF 1,4-CYCLOHEXANEDIMETHANOL FROM TEREPHTHALIC ACID [FR] PROCÉDÉ DE PRÉPARATION DE 1,4-CYCLOHEXANEDIMÉTHANOL À PARTIR D'ACIDE TÉRÉPHTALIQUE
The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
[EN] BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] COMPOSÉS BENZAMIDES ET IMIDAZOPYRAZINES UTILISÉS COMME INHIBITEURS DE LA BTK
申请人：MERCK SHARP & DOHME
公开号：WO2016106623A1
公开（公告）日：2016-07-07
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.
Birch‐Type Photoreduction of Arenes and Heteroarenes by Sensitized Electron Transfer
作者：Anamitra Chatterjee、Burkhard König
DOI：10.1002/anie.201905485
日期：2019.10
energy-transfer and electron-transfer processes generates an arene radical anion, which is subsequently trapped by hydrogen-atom transfer and finally protonated to form the dearomatized product. The photoreduction converts planar aromatic feedstock compounds into molecular skeletons that are of use in organic synthesis.
[EN] HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS D'ACIDE HYDROXAMIQUE ET LEUR UTILISATION DANS LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
申请人：ACHAOGEN INC
公开号：WO2012154204A1
公开（公告）日：2012-11-15
Antibacterial compounds of Formula I are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; use of such compounds in the treatment of bacterial infections and processes for the preparation of such compounds.
[EN] SSAO INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE SSAO ET LEUR UTILISATION
申请人：ECCOGENE SHANGHAI CO LTD
公开号：WO2021083209A1
公开（公告）日：2021-05-06
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of formula (I') or (I), and a method of treating or preventing a disease in which SSAO plays a role.
